About Clinical Trial Results
Motivated by the premise that every trial, regardless of outcome, can have a benefit to the research community, Clinical Trial Results (CTR) from The Oncologist promotes the mission of sharing results and speeding discoveries.
Despite the U.S. federal mandate to report findings of certain clinical trials, the outcomes of many still go unreported. When results are published, their publication lags behind the trial completion by a median of 21 months.* This results in a great loss of valuable information, redundant control groups, and waste of other resources.
In the spirit of cooperation and transparency, CTR offers a powerful solution with an easy online format to encourage the publication of results not otherwise reported. Currently accepting submissions for phase I and phase II trails, CTR facilitates fast-track dissemination of results through a brief Author Summary in print, with an online component offering more extensive clinical findings, pharmacokinetics, adverse event reporting, and full-length discussion.
Designed specifically for the submission of clinical trials, CTR's technical functionalities include the ability to create waterfall plots, adverse event tables, and Kaplan-Meier curves from the investigators' data. To ensure that results are easily discoverable, CTR is fully indexed in MEDLINE/PubMed.
*Ross, JS, Tse T, Zarin DA et al. Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis. BMJ 2012;344:d7292.
Read the Frequently Asked Questions and Submission Steps here: http://authors.theoncologist.com/images/CTRFAQs.pdf
View the entire collection of published CTRs here: http://theoncologist.alphamedpress.org/site/misc/PublishedClinicalTrialResults.xhtml
- A brief Author Summary, to be published in print. This summary allows the reader to quickly grasp the aim and design of the study. It is made up of a structured abstract (200 words or less) containing four sections: Background, Methods, Results, and Conclusion; followed by a brief Discussion. This Discussion can take one of two forms:
- 350 words and two salient graphics, such as a table, schema, waterfall plot, image or graph
- 450 words with a single salient graphic
- The full data set, incorporating all supporting documentation and an extended Discussion, to be published online. Authors are allowed 1000 words for the extended online Discussion; they are encouraged to be thorough, yet concise. The sponsor, coordinating site, participating sites, and investigators should all be clearly identified.
The data published online remains the property of the author(s).
The Author Summary and the full Clinical Trial Results share a title and are PubMed citable with their own DOI (Document Object Identifier).
Join the mission of improving clinical trial design and efficiency by submitting results today.